Literature DB >> 27515377

Clinical and hemodynamic results after direct transcatheter aortic valve replacement versus pre-implantation balloon aortic valvuloplasty: A case-matched analysis.

Carlos Ferrera1, Luis Nombela-Franco1, Eulogio Garcia2, Pilar Jimenez-Quevedo1, Corina Biagioni1, Nieves Gonzalo1, Ivan Nuñez-Gil1, Ana Viana-Tejedor1, Pablo Salinas1, Jose Alberto de Agustin1, Carlos Almeria1, Fabian Islas1, Leopoldo Perez de Isla1, Cristina Fernandez-Perez3, Javier Escaned1, Antonio Fernández-Ortiz1, Carlos Macaya1.   

Abstract

OBJECTIVES: To evaluate the safety and midterm hemodynamic results of direct transcatheter aortic valve replacement (TAVR) without pre-implantation balloon aortic valvuloplasty (BAV).
BACKGROUND: BAV was considered a mandatory previous step in TAVR procedures.
METHODS: A total of 339 consecutive patients who underwent transfemoral TAVR were prospectively selected. A 1:1 matching was conducted, pairing age, prosthesis type (self-expandable or balloon expandable) and size, and valve calcification grade (48% with moderate to severe valve calcification). Finally, 102 pairs (102 patients with previous BAV and 102 without BAV) were obtained.
RESULTS: Direct TAVR was feasible in all patients without any crossover to BAV group. Device success was achieved in 91.2% and 90.2% of cases in direct TAVR and pre-BAV groups (P = 0.810), respectively, without any differences in balloon postdilation rate and residual aortic regurgitation. The amount of contrast agent, acute kidney injury and myocardial injury was significantly lower in the direct implantation group (P < 0.05). No differences were found in 30-day and 1-year mortality between both groups (4.9% vs. 9.8%, P = 0.177 and 14.0% vs. 23.8%, P = 0.771, respectively). Hemodynamic parameters remained stable after 1-year follow-up in both groups.
CONCLUSIONS: Direct transfemoral TAVR without prior BAV was safe in patients with calcified severe aortic stenosis. Pre-implantation BAV could be omitted in patients undergoing TAVR, without influence in procedure success rate, and subsequent patients' clinical course and valve hemodynamic performance.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  TAVI; TAVR; balloon aortic valvuloplasty predilation; postdilation; transcatheter aortic valve replacement

Mesh:

Year:  2016        PMID: 27515377     DOI: 10.1002/ccd.26671

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  5 in total

1.  Predilatation Prior to Transcatheter Aortic Valve Implantation: Is it Still a Prerequisite?

Authors:  Matteo Pagnesi; Luca Baldetti; Paolo Del Sole; Antonio Mangieri; Marco B Ancona; Damiano Regazzoli; Nicola Buzzatti; Francesco Giannini; Antonio Colombo; Azeem Latib
Journal:  Interv Cardiol       Date:  2017-09

2.  Routine Predeployment Balloon Aortic Valvuloplasty During Transcatheter Aortic Valve Replacement: Time to Move On?

Authors:  Marie-France Poulin; Clifford J Kavinsky
Journal:  J Am Heart Assoc       Date:  2017-02-18       Impact factor: 5.501

3.  Trend and Outcomes of Direct Transcatheter Aortic Valve Replacement from a Single-Center Experience.

Authors:  Anthony A Bavry; Seyed Hossein Aalaei-Andabili; Ki E Park; Calvin Y Choi; Eddie W Manning Iii; Wade W Stinson
Journal:  Cardiol Ther       Date:  2018-08-14

4.  Balloon-expandable transfemoral transcatheter aortic valve implantation with or without predilation: findings from the prospective EASE-IT TF multicentre registry.

Authors:  Gerhard Schymik; Tanja Rudolph; Claudius Jacobshagen; Jürgen Rothe; Hendrik Treede; Sebastian Kerber; Derk Frank; Lenka Sykorova; Maki Okamoto; Martin Thoenes; Cornelia Deutsch; Peter Bramlage; Christian Butter
Journal:  Open Heart       Date:  2019-10-03

5.  The use of semi-compliant versus non-compliant balloon systems for predilatation during the implantation of self-expandable transcatheter aortic valves: Data from the VIenna CardioThOracic Aortic Valve RegistrY (VICTORY).

Authors:  Markus Mach; Philipp Szalkiewicz; Thomas Poschner; Waseem Hasan; Martin Andreas; Bernhard Winkler; Ena Hasimbegovic; Theresia Steinkellner; Andreas Strouhal; Christopher Adlbrecht; Georg Delle-Karth; Martin Grabenwöger
Journal:  Eur J Clin Invest       Date:  2021-05-06       Impact factor: 4.686

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.